discontinuation of ACEI/ARB for COVID-19: living meta-analysis of clinical studies

Outcome	Relative effect 95%CI	Trt. better when	I2	k (RCT/OBS)	Bayesian probability	Overall ROB	Publication bias	Endpoint importance	Published MA
efficacy endpoints 00
deaths	0.97 [0.38, 2.50]	< 1	0%	1 study (2/-)	52.5 %	NA	not evaluable	crucial	-
mechanical ventilation	1.25 [0.76, 2.06]	< 1	0%	1 study (1/-)	19.1 %	NA	not evaluable	important	-
ICU admission	0.82 [0.37, 1.82]	< 1	0%	1 study (1/-)	68.7 %	NA	not evaluable	non important	-

LoD: level of statistical demonstration: Statistically conclusive: statistically significant with a strict control of overall risk of type 1 error (statistically demonstrated), does not take into account the risk of bias; suggested: nominally statistically significant but without a strict control of overall risk of type 1 error; inconclusive: not nominally statistically significant; safety concerns;
Bayesian probability: Bayesian posterior probability of treatment effect (computed with a noninformative prior); ROB: risk of bias; k: number of studies; published MA: number of published meta-analysis on the same topic; degree of certainty adapted from GRADE. Trt. better when: indicates when the relative treatment effect shows that the studied treatment is better than control.

discontinuation of ACEI/ARB - versus continuation of ACEI/ARB - for COVID 19 hospitalized pdf xlsx method abbreviations

efficacy endpoints 00